Psoriasis Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

For patients with skin conditions (general requirements):

• People who are able to understand and sign a written consent form before any study procedures begin
• People who are male or non-pregnant female, aged 18 or older
• People who are willing to avoid extensive washing, bathing, or swimming of the affected skin area for 12 hours before each study visit
• People who are willing and able to follow the study schedule and requirements
• Female participants who are willing to avoid becoming pregnant from the start of the study until the last visit (month 12)
• People who are willing to begin the treatment prescribed as part of the study

For people with Atopic Dermatitis (eczema):

• People with a confirmed diagnosis of chronic, moderate-to-severe eczema (meeting standard diagnostic criteria) for at least 3 years before joining
• People who have recent records (within the last 6 months) showing their condition was serious enough to warrant treatment with immune-suppressing medicines, biologics, or JAK-inhibitor medicines
• People who have recent records (within the last 6 months) showing that previous treatments did not work well enough, where applicable
• People with a disease severity score (EASI) of 7 or higher at the time of joining
• People who have at least one suitable affected skin area identified by the study doctor
• People who are about to start treatment with one of the following medicines: cyclosporine A, dupilumab, tralokinumab, lebrikizumab, abrocitinib, or upadacitinib

For people with Cutaneous Lupus Erythematosus (CLE — a form of lupus affecting the skin):

• People with a confirmed diagnosis of CLE (including SCLE, CDLE, or LET types), confirmed through skin examination and laboratory testing
• People with a disease activity score (CLASI-A) of 3 or higher, not counting hair loss or mouth ulcers
• People who are about to start treatment with topical corticosteroids, hydroxychloroquine, or methotrexate (alone or in combination)

For people with Chronic Spontaneous Urticaria (CSU — long-term hives with no clear cause):

• People with a confirmed diagnosis of moderate-to-severe CSU lasting at least 3 months, whose symptoms continue despite taking second-generation antihistamine tablets (at up to four times the standard approved dose)
• People currently taking antihistamines who have been on a stable dose for at least 2 weeks before the study starts, and who are willing to keep that dose the same throughout the study
• People who are about to start treatment with omalizumab, cyclosporine A, or a BTK inhibitor (where that medicine is approved and covered by health insurance in the Netherlands)

For people with Hidradenitis Suppurativa (HS — a skin condition causing painful lumps):

• People with a history of moderate-to-severe HS (based on a standard scoring system) for at least 1 year before joining
• People who are about to start treatment with anti-TNF or anti-IL17 medicines (such as secukinumab or bimekizumab, where approved and covered in the Netherlands)

For people with Mycosis Fungoides (MF — a type of skin lymphoma):

• People with a confirmed diagnosis of cutaneous T-cell lymphoma (CTCL), MF type, confirmed through tissue sampling or clinical assessment
• People in early stages (IA–IIA) who have at least one patch or plaque lesion present
• People who are about to start treatment with topical chlormethine, topical corticosteroids, or light therapy (PUVA or UV-B)

For people with Psoriasis (PSO):

• People with a confirmed diagnosis of chronic plaque psoriasis for at least 6 months before joining
• People with a psoriasis severity score (PASI) of 5 or higher, with at least one suitable affected skin area identified by the study doctor
• People who are about to start treatment with a biologic medicine, including anti-TNF, anti-IL23, anti-IL17, or anti-TYK2 medicines

For healthy volunteers:

• People who are male or non-pregnant female, aged 18 or older
• People who are in stable good health, as assessed by the study doctor
• People with no significant skin disease, as judged by the study doctor
• People with no history of raised or thickened scarring (hypertrophic scarring or keloid)
• People willing to avoid extensive washing or bathing of the study skin area for 12 hours before each visit
• People willing to stop using any skin treatments (prescription or over-the-counter) on the study area for 2 weeks before the study starts
• People willing to avoid applying any skin products (creams, ointments, lotions) to the skin 24 hours before each study visit
• People willing to stop any antibiotic treatment for 14 days before the study starts
• People willing and able to follow the full study schedule
• Female participants who are willing to avoid becoming pregnant from the start of the study until the last visit

Who may not be able to join:

For patients (general):

• People who have another skin infection or skin disease in the area being studied, other than their main condition
• People who have taken an unapproved experimental drug within 4 weeks before joining
• People who have any other condition or health factor that the study doctor believes could interfere with the study
• People who have recently used certain treatments within the preferred washout period (confirm with trial site): topical treatments within 1 week; light therapy within 4 weeks; non-biologic systemic treatments within 4 weeks; radiotherapy or surgery in the treatment area within 8 weeks; biologic medicines within 8 weeks; chemotherapy within 3 months — note that these are preferred waiting periods and are not strict exclusion rules, as this is a real-world study

For people with CLE specifically:

• People who have been diagnosed with systemic lupus erythematosus (SLE — lupus affecting internal organs)

For people with CSU specifically:

• People who have received omalizumab within 8 weeks before the study starts
• People whose hive or swelling symptoms are caused by other specific conditions, such as urticarial vasculitis, erythema multiforme, cutaneous mastocytosis, or inherited or drug-induced angioedema (confirm with trial site)

For people with MF specifically:

• People with an ongoing, uncontrolled active skin infection (other than a secondary infection of MF lesions, as judged by the study doctor)

For people with Psoriasis specifically:

• People whose psoriasis is primarily of the erythrodermic, pustular, or guttate type
• People with psoriasis that was caused by a medication

For healthy volunteers:

• People with a history of immune system problems, such as immune suppression, severe allergies, or anaphylaxis, that the study doctor believes could affect the study
• People with any significant uncontrolled health condition (such as neurological, psychiatric, heart, lung, digestive, liver, or kidney conditions) that the study doctor believes could affect the study
• People who have used systemic antibiotic treatment for more than 2 months in total during the past 12 months
• People who have used any immune-suppressing or immune-modifying treatment within the 30 days before the study starts
• People who have donated or lost more than 500mL of blood in the 3 months before joining, or who have participated in another drug study within 3 months before joining or more than 4 times in the past year
• People who have been drinking more than 5 standard alcoholic drinks per day on average in the 3 months before joining; alcohol must also be avoided for at least 24 hours before each study visit
• People who test positive for drugs in a urine test at the start of the study, or who have a history of drug misuse
• People who have had high levels of UV (sun or sunbed) exposure within 3 weeks before the first visit, or who cannot avoid this during the study
• People who have done intense physical exercise within 48 hours before any study visit
• People with any other condition or known factor that the study doctor believes could interfere with the study

Important: Always verify eligibility with the trial site directly before applying.